Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)

Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5) Publisher Pubmed

Allahyari A¹ ; Ehsanpour A² ; Najafi B³ ; Ansarinejad N⁴ ; Mehrzad V⁵ ; Kalantari B⁶ ; Raafat J⁷ ; Ghadiany M⁸ ; Shahi F⁹ ; Gharib B¹⁰ ; Moazed V¹¹ ; Khosravi A¹² ; Mirpour MH¹³ ; Salari S¹⁴ Show All Authors

Allahyari A¹
Ehsanpour A²
Najafi B³
Ansarinejad N⁴
Mehrzad V⁵
Kalantari B⁶
Raafat J⁷
Ghadiany M⁸
Shahi F⁹
Gharib B¹⁰
Moazed V¹¹
Khosravi A¹²
Mirpour MH¹³
Salari S¹⁴
Mortazavizadeh S¹⁵
Nekoyi A¹⁶
Khani M¹⁷
Sadeghi A¹⁸
Gharib S¹⁹
Bary A²⁰
Mirzania M²¹
Haghighat S²²
Razavi SM²³
Emami SAH²⁴
Hosseinzadeh M²⁵
Mirbolouk M²⁶
Sadighi S²⁷
Shahrasbi A²⁸
Esfahani A²⁹
Gity M³⁰
Anjidani N³¹
Kaf H³¹
Najaf S³²

Source: BMC Cancer Published:2022

Abstract

Following publication of the original article [1], the authors identified that Behrouz Najafi was omitted as the third author in the author group. The author group in this correction article has been updated and the original article [1] has been corrected. © The Author(s) 2022.

2. Correction To: Association of Enos and Ace Gene Polymorphisms As a Genetic Risk Factor in Gestational Diabetes in Iranian Women (Journal of Diabetes & Metabolic Disorders, (2018), 17, 2, (123-127), 10.1007/S40200-018-0348-4), Journal of Diabetes and Metabolic Disorders (2020)

Experts (# of related papers)

Fatemeh Khoshnavay Fomani (1)

Style	Citing Format
MLA	Allahyari A, et al.. "Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)." BMC Cancer, vol. 22, no. 1, 2022, pp. -.
APA	Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, ... Najaf S (2022). Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5). BMC Cancer, 22(1), -.
Chicago	Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, et al.. "Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)." BMC Cancer 22, no. 1 (2022): -.
Harvard	Allahyari A et al. (2022) 'Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)', BMC Cancer, 22(1), pp. -.
Vancouver	Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, et al.. Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5). BMC Cancer. 2022;22(1):-.
BibTex	@article{ author = {Allahyari A and Ehsanpour A and Najafi B and Ansarinejad N and Mehrzad V and Kalantari B and Raafat J and Ghadiany M and Shahi F and Gharib B and Moazed V and Khosravi A and Mirpour MH and Salari S and Mortazavizadeh S and Nekoyi A and Khani M and Sadeghi A and Gharib S and Bary A and Mirzania M and Haghighat S and Razavi SM and Emami SAH and Hosseinzadeh M and Mirbolouk M and Sadighi S and Shahrasbi A and Esfahani A and Gity M and Anjidani N and Kaf H and Najaf S}, title = {Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)}, journal = {BMC Cancer}, volume = {22}, number = {1}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Allahyari A AU - Ehsanpour A AU - Najafi B AU - Ansarinejad N AU - Mehrzad V AU - Kalantari B AU - Raafat J AU - Ghadiany M AU - Shahi F AU - Gharib B AU - Moazed V AU - Khosravi A AU - Mirpour MH AU - Salari S AU - Mortazavizadeh S AU - Nekoyi A AU - Khani M AU - Sadeghi A AU - Gharib S AU - Bary A AU - Mirzania M AU - Haghighat S AU - Razavi SM AU - Emami SAH AU - Hosseinzadeh M AU - Mirbolouk M AU - Sadighi S AU - Shahrasbi A AU - Esfahani A AU - Gity M AU - Anjidani N AU - Kaf H AU - Najaf S TI - Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5) JO - BMC Cancer VL - 22 IS - 1 SP - EP - PY - 2022 ER -

Style

Citing Format

MLA

Allahyari A, et al.. "Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)." BMC Cancer, vol. 22, no. 1, 2022, pp. -.

APA

Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, ... Najaf S (2022). Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5). BMC Cancer, 22(1), -.

Chicago

Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, et al.. "Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)." BMC Cancer 22, no. 1 (2022): -.

Harvard

Allahyari A et al. (2022) 'Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)', BMC Cancer, 22(1), pp. -.

Vancouver

Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, et al.. Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5). BMC Cancer. 2022;22(1):-.

BibTex

@article{ author = {Allahyari A and Ehsanpour A and Najafi B and Ansarinejad N and Mehrzad V and Kalantari B and Raafat J and Ghadiany M and Shahi F and Gharib B and Moazed V and Khosravi A and Mirpour MH and Salari S and Mortazavizadeh S and Nekoyi A and Khani M and Sadeghi A and Gharib S and Bary A and Mirzania M and Haghighat S and Razavi SM and Emami SAH and Hosseinzadeh M and Mirbolouk M and Sadighi S and Shahrasbi A and Esfahani A and Gity M and Anjidani N and Kaf H and Najaf S}, title = {Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)}, journal = {BMC Cancer}, volume = {22}, number = {1}, pages = {-}, year = {2022} }

RIS

TY - JOUR
AU - Allahyari A
AU - Ehsanpour A
AU - Najafi B
AU - Ansarinejad N
AU - Mehrzad V
AU - Kalantari B
AU - Raafat J
AU - Ghadiany M
AU - Shahi F
AU - Gharib B
AU - Moazed V
AU - Khosravi A
AU - Mirpour MH
AU - Salari S
AU - Mortazavizadeh S
AU - Nekoyi A
AU - Khani M
AU - Sadeghi A
AU - Gharib S
AU - Bary A
AU - Mirzania M
AU - Haghighat S
AU - Razavi SM
AU - Emami SAH
AU - Hosseinzadeh M
AU - Mirbolouk M
AU - Sadighi S
AU - Shahrasbi A
AU - Esfahani A
AU - Gity M
AU - Anjidani N
AU - Kaf H
AU - Najaf S
TI - Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)
JO - BMC Cancer
VL - 22
IS - 1
SP -
EP -
PY - 2022
ER -

Science Communicator Platform

Authors

Abstract